Budesonide/mesalazine suppository - Dr. Falk Pharma

Drug Profile

Budesonide/mesalazine suppository - Dr. Falk Pharma

Alternative Names: mesalazine/budesonide suppository

Latest Information Update: 24 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dr Falk Pharma
  • Class Aminosalicylic acids; Anti-inflammatories; Antiallergics; Glucocorticoids; Irritable bowel syndrome therapies; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Ulcerative proctitis

Most Recent Events

  • 24 Feb 2016 No recent reports on development identified - Phase-II for Ulcerative proctitis in Germany (Rectal)
  • 01 Aug 2015 Dr. Falk Pharma completes a phase II trial in Ulcerative proctitis in Germany (Rectal) (NCT01966783)
  • 01 Sep 2013 Phase-II clinical trials in Ulcerative proctitis in Germany (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top